Kintara and TuHURA enter definitive merger; combined company to focus on immuno-oncology

TuHURA Biosciences, Inc./NV

TuHURA stockholders to own ~97.15% of combined company; Kintara stockholders ~2.85% (or 94.55%/5.45% after CVR shares).
Combined company to trade as 'HURA' on Nasdaq; merger expected to close in Q3 2024.
TuHURA plans Phase 3 trial for IFx-2.0 personalized cancer vaccine in 2H 2024 under FDA accelerated approval pathway.
TuHURA has $31M subscribed financing of convertible notes to provide cash runway into late 2025.
CVRs issued to Kintara stockholders; up to 53.9M shares if milestone on REM-001 study met by Dec 31, 2025.

item 1.01 item 5.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

TuHURA Biosciences, Inc./NV entered into Agreement and Plan of Merger with Kintara Therapeutics, Inc., Kayak Mergeco, Inc. (effective 2024-04-02).

Action: entry
Agreement: merger
Counterparty: Kintara Therapeutics, Inc., Kayak Mergeco, Inc.
Effective: 2024-04-02

Exact text from the filing

On April 2, 2024, Kintara Therapeutics, Inc. (“ Kintara ”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“ Merger Sub ”), and TuHURA Biosciences, Inc., a Delaware corporation (“ TuHURA ”), entered into an Agreement and Plan of Merger

View on SEC.gov

380 material agreements filed in the last 30 days. Browse all material agreements →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-24-040655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.